NYU Langone Health

https://nyulangone.org/

NYU Langone Health is an integrated academic health system headquartered in New York City, New York. Its core mission is "to care, to teach, to discover," encompassing excellence in patient care, biomedical research, and medical education. The system operates as a world-class, patient-centered institution, serving as one of the nation's premier centers for healthcare delivery and scientific advancement.

The health system provides a comprehensive range of medical services across more than 75 divisions of specialty care. Key offerings include primary care, virtual urgent care, advanced imaging services, orthopedics, heart and brain/spine care, and specialized treatment through the Perlmutter Cancer Center and Hassenfeld Children's Hospital. With seven inpatient facilities and over 320 outpatient locations, NYU Langone Health extends its services throughout the New York City region and into Florida. It also includes the NYU Grossman School of Medicine and NYU Grossman Long Island School of Medicine, both known for offering tuition-free medical education.

Under the leadership of Dean and CEO Alec C. Kimmelman, MD, PhD, NYU Langone Health maintains a strong market position, consistently ranking among the top integrated academic medical centers nationally. It has received numerous accolades for patient safety and quality, including 11 consecutive "A" Leapfrog Hospital Safety Grades and Magnet® Recognition for nursing excellence across all its hospitals. Recent notable activities include ongoing research breakthroughs in areas such as immunology and neuroscience, expansion of its network with new locations, and the full acquisition of Long Island Community Hospital (now NYU Langone Hospital – Suffolk) in 2025.

Latest updates

Gut Bacteria Link to Lupus Nephritis Offers Novel Therapeutic Pathway

Event summary

  • NYU Langone Health researchers have identified a link between the gut bacterium *Ruminococcus gnavus* and the development of lupus nephritis, a severe kidney complication of lupus.
  • Elevated levels of a lipoglycan molecule produced by *Ruminococcus gnavus* appear to trigger immune responses and inflammation in patients with lupus nephritis.
  • The study suggests that antibiotics targeting *Ruminococcus gnavus* or the TLR2 immune protein could offer an alternative to current immunosuppressant therapies.
  • Mouse model experiments confirmed that exposure to *Ruminococcus gnavus* induced lupus-like inflammation and kidney damage, while blocking TLR2 mitigated these effects.
  • NYU Langone Health has patented intellectual property related to detection of antilipoglycan antibodies and potential treatments.

The big picture

This research represents a significant shift in understanding lupus nephritis, moving away from solely immunosuppressive treatments towards microbiome-targeted therapies. The potential to identify at-risk patients early and intervene with antibiotics or TLR2 blockers could significantly improve outcomes for a disease affecting a disproportionate number of women and minority populations. The findings also highlight the growing recognition of the gut microbiome's role in systemic autoimmune diseases, opening up new avenues for therapeutic intervention across a range of conditions.

What we're watching

Clinical Adoption
The speed of clinical adoption of this biomarker-driven therapeutic approach will depend on the validation of antilipoglycan antibodies in larger patient cohorts and the demonstration of clinical efficacy in trials.
Patent Landscape
The strength and breadth of NYU Langone’s patents surrounding antilipoglycan antibody detection and treatment will influence the commercial viability and licensing opportunities for this approach.
Regulatory Pathway
The regulatory pathway for antibiotics targeting the gut microbiome, particularly for a chronic autoimmune condition, may present unique challenges and require novel approval strategies.

Neutrophil Ratio May Predict Alzheimer's Risk Years in Advance

Event summary

  • NYU Langone Health researchers identified a correlation between elevated neutrophil to lymphocyte ratio (NLR) and increased risk of Alzheimer's disease and related dementias.
  • The study analyzed NLR data from nearly 400,000 patients across two healthcare systems, including 285,000 from NYU Langone and 85,000 from the Veteran's Health Administration.
  • The elevated NLR was observed *before* any signs of cognitive impairment, suggesting a potential role in disease progression.
  • The study found a higher risk associated with elevated NLR in Hispanic patients and women across both healthcare systems.

The big picture

This research highlights the growing recognition of immune system dysfunction as a potential driver of neurodegenerative diseases. The ease of NLR measurement from standard blood tests offers a potentially low-cost, accessible screening tool, but its predictive power will depend on further validation and integration with other risk factors. The findings underscore the shift towards preventative and early intervention strategies in Alzheimer's disease management, which could significantly impact healthcare spending and patient outcomes in the future.

What we're watching

Ethnic Disparities
The observed higher risk in Hispanic patients warrants further investigation to determine if genetic or socioeconomic factors are contributing to the correlation, potentially impacting screening strategies.
Clinical Validation
The NLR's utility as a diagnostic tool will depend on validation in larger, more diverse patient cohorts and its integration with existing risk assessment models.
Therapeutic Targets
The VIDA lab's research into neutrophil activity's role in dementia progression could reveal novel therapeutic targets, although establishing causality remains a significant hurdle.

NYU Study Reveals Discrepancy in Heat Risk Thresholds for Vulnerable Older Adults

Event summary

  • Researchers at NYU Langone Health System found that older adults in a climate-vulnerable population experienced heat-associated emergency care risks starting at a heat index of 66°F, significantly lower than current municipal heat advisories (95°F+).
  • The study, published March 20, 2026, analyzed electronic health record data from two New York City emergency departments serving distinct patient populations.
  • ED-1, serving a more vulnerable population (minority, Medicaid recipients), showed a 90-101°F range of amplified risk, while ED-2 (higher-income, privately insured) showed no significant association.
  • If a healthcare-system based heat warning had been triggered at 90°F, approximately 116 ED visits at ED-1 could have been prevented during the study period (2022-2024).

The big picture

This study highlights a critical disconnect between population-level heat advisories and the actual risk experienced by vulnerable populations, particularly older adults with chronic conditions. The reliance on broad, standardized thresholds may be inadequate, underscoring the need for localized, data-driven approaches to public health interventions. The findings suggest a broader trend toward personalized risk assessments and targeted interventions within healthcare, driven by the increasing availability of electronic health record data.

What we're watching

Implementation Lag
The adoption rate of these lower heat thresholds by other healthcare systems and municipalities will be a key indicator of whether this research translates into tangible improvements in patient outcomes.
Data Bias
Further research is needed to determine if these findings are replicable across different geographic locations and patient demographics, acknowledging the study's focus on New York City.
Systemic Factors
How social and structural risk factors (e.g., housing instability, access to cooling centers) interact with individual health vulnerabilities to exacerbate heat-related illness will be critical to understand for effective intervention strategies.

NYU Langone Secures $25M NIH Grant to Coordinate Human Biology Data

Event summary

  • NYU Langone Health and Sage Bionetworks received a $25 million, 5-year grant from the NIH to establish a data hub and coordinating center.
  • The grant supports the Complement-Animal Research in Experimentation (Complement-ARIE) program, focused on developing New Approach Methodologies (NAMs).
  • The NYU-Sage NAMs Data Hub and Coordination Center (NYU-Sage NDHCC) will standardize and harmonize NAMs data using a 'FUSION' framework.
  • The NDHCC will foster collaboration through workshops, competitions, and engagement with industry and regulatory experts.

The big picture

The NIH's investment signals a strategic shift towards reducing reliance on animal testing in biomedical research, driven by the promise of more accurate and human-relevant models. This initiative represents a significant opportunity for companies developing NAM technologies, but also introduces complexities in data standardization and regulatory validation. The $25 million grant underscores the growing importance of data infrastructure in accelerating scientific discovery and potentially reshaping the drug development pipeline.

What we're watching

Data Governance
The success of the NDHCC hinges on the adoption and interoperability of the FUSION framework across the Complement-ARIE consortium; resistance to standardized data formats could significantly impede progress.
Regulatory Approval
The Validation and Qualification Network's ability to establish criteria for NAMs validation will be critical for eventual regulatory acceptance and commercialization of these technologies.
Technology Adoption
The pace at which NAMs replace traditional animal research models will depend on demonstrating their cost-effectiveness and predictive accuracy compared to existing methods.

NYU Langone Study Demonstrates Potential of Targeted Radio Wave Brain Stimulation

Event summary

  • NYU Langone researchers have developed a technique called Transcranial Radio Frequency Stimulation (TRFS) for potential treatment of neurological conditions.
  • The study, published in *Brain Stimulation*, demonstrates TRFS's ability to adjust neural activity in mice, targeting specific brain regions or the entire organ.
  • TRFS utilizes customized antennae to deliver high-frequency signals, influencing ion flow and nerve signaling – either suppressing or encouraging activity.
  • The research builds on existing RF wave usage in MRI and cancer treatment, but marks the first demonstration of direct brain stimulation via this method.
  • The technique was shown to alter behavior in mice by modulating striatal neuron activity, demonstrating directional control.

The big picture

The development of TRFS addresses a significant unmet need for non-invasive treatments for neurological disorders, which collectively affect a substantial portion of the global population. Current treatments, including pharmaceuticals and surgery, often face limitations in efficacy and safety. This technology, if successful, could represent a paradigm shift in how brain disorders are managed, potentially reducing reliance on existing, less effective interventions. The research leverages existing radio frequency technology, suggesting a relatively low barrier to entry for further development and commercialization, though significant clinical validation is required.

What we're watching

Clinical Translation
The speed at which TRFS transitions from animal studies to human clinical trials will be a key indicator of its long-term viability, given the complexity of human brain anatomy and ethical considerations.
Regulatory Pathway
The FDA’s approach to regulating a neuromodulation technique like TRFS, particularly concerning safety and efficacy, will significantly impact its commercialization timeline and potential market access.
Competitive Landscape
The emergence of competing non-invasive brain stimulation technologies and the potential for intellectual property disputes will shape the competitive dynamics within the neurological treatment space.

LCN2 Antibody Therapy Shows Promise in Lung, Pancreatic Cancer Mouse Models

Event summary

  • NYU Langone Health researchers identified lipocalin 2 (LCN2) as a protein released by stressed cancer cells that helps tumors evade the immune system.
  • Blocking LCN2 with an antibody therapy in mice slowed tumor growth and increased T-cell infiltration, demonstrating improved efficacy when combined with existing immunotherapies.
  • Analysis of tumor samples from over 130 lung and pancreatic cancer patients linked high LCN2 levels to a median survival of 52 months, compared to 79 months for patients with low levels.
  • The study, published in Nature on February 18, 2026, implicates the integrated stress response (ISR) and ATF4 in LCN2 production and tumor immune evasion.

The big picture

This research highlights a novel mechanism by which tumors evade the immune system, offering a potential new therapeutic target. The discovery of LCN2's role in immunosuppression could significantly impact the development of next-generation immunotherapies, particularly for aggressive cancers like lung and pancreatic cancer, which have historically shown limited response to existing treatments. The findings also underscore the importance of understanding cellular stress responses in cancer progression and immune evasion.

What we're watching

Clinical Trials
The translation of these promising mouse model results to human clinical trials will be critical to assess the efficacy and safety of LCN2-targeted therapies in lung and pancreatic cancer patients.
Mechanism Validation
Further research is needed to validate whether the LCN2/ATF4 pathway is active in other cancer types resistant to immunotherapy, potentially broadening the therapeutic application.
Commercialization
The involvement of multiple co-founders and advisors with equity stakes in related biotech companies (Aethon Therapeutics, Revalia Bio) suggests potential for rapid commercialization and licensing opportunities.

NYU Langone Identifies Key Protein Driving Melanoma Growth, Immune Evasion

Event summary

  • NYU Langone researchers have identified HOXD13, a transcription factor, as a key driver of melanoma growth and immune evasion.
  • HOXD13 promotes angiogenesis by stimulating pathways involving VEGF, SEMA3A, and CD73, and suppresses cytotoxic T cell activity.
  • Suppression of HOXD13 led to tumor shrinkage and increased T cell infiltration in experiments.
  • Clinical trials are already underway testing VEGF and adenosine-receptor inhibitors, with plans to combine them for HOXD13-driven melanoma.
  • The research analyzed tumor samples from over 200 melanoma patients across three countries (U.S., Brazil, Mexico).

The big picture

The identification of HOXD13 as a central regulator in melanoma progression represents a significant advancement in cancer research, potentially opening new avenues for targeted therapies. This discovery aligns with the broader trend of leveraging genomic insights to develop personalized cancer treatments, particularly those that combine immunotherapy with targeted drug approaches. The potential application of this approach to other cancers, such as glioblastomas and sarcomas, could significantly expand the market opportunity for these therapies.

What we're watching

Clinical Progress
The success of ongoing clinical trials evaluating VEGF and adenosine-receptor inhibitors will be crucial in determining the viability of a combined treatment approach for HOXD13-driven melanoma.
Expansion Potential
How effectively Hernando-Monge’s team can expand the targeting of VEGF and adenosine pathways to other cancers with elevated HOXD13 will influence the therapeutic impact of this discovery.
Mechanism Validation
Whether the observed correlation between HOXD13 levels and T cell suppression in melanoma patients holds true in larger, more diverse patient cohorts needs to be validated.

NYU Langone Taps MSK Leader to Drive Radiation Oncology Research

Event summary

  • Daniel Gomez, MD, MBA, has been appointed Chair of the Department of Radiation Oncology at NYU Langone Perlmutter Cancer Center, effective February 9, 2026.
  • Dr. Gomez joins from Memorial Sloan Kettering Cancer Center, where he held roles including Director of Thoracic Radiation Oncology and Vice Chair of Clinical Operations.
  • His research focuses on lung cancer and radiation therapy for oligometastatic disease, including co-leading the NRG-LU002 trial.
  • Dr. Gomez holds an MBA from Rice University and has expertise in AI applications within healthcare.

The big picture

The appointment of Dr. Gomez signals NYU Langone's commitment to expanding its research capabilities and enhancing its competitive position within the highly specialized and competitive cancer care market. His expertise in oligometastatic disease management addresses a growing segment of cancer patients requiring complex, multidisciplinary care. The move also highlights the ongoing consolidation and talent shuffling within leading cancer centers as they vie for research funding and patient referrals.

What we're watching

Research Focus
Dr. Gomez's emphasis on oligometastatic cancers and biomarker-integrated therapies suggests a shift towards more personalized and targeted radiation approaches at NYU Langone, potentially impacting clinical trial recruitment and patient outcomes.
Talent Migration
The movement of a senior leader from Memorial Sloan Kettering to NYU Langone indicates a potential talent war within the cancer care landscape, and could influence future hiring strategies at both institutions.
AI Integration
Given Dr. Gomez’s training in AI for healthcare, the department will likely explore and implement AI-driven tools for treatment planning and patient management, which could improve efficiency and precision.

Brain Research Unlocks 'One-Shot Learning,' Could Accelerate AI Development

Event summary

  • NYU Langone Health researchers have identified the high-level visual cortex (HLVC) as the brain region responsible for 'one-shot learning,' the ability to recognize objects after seeing them only once.
  • The research, published in Nature Communications on February 4, 2026, links impaired one-shot learning to neurological disorders like schizophrenia and Parkinson's disease.
  • Researchers used fMRI, EEG, and a vision transformer AI model to map brain activity and replicate human one-shot learning capabilities.
  • The AI model, a vision transformer, demonstrated human-like one-shot learning, surpassing other AI models lacking a comparable prior module.
  • The findings suggest a potential pathway for developing AI models capable of learning from minimal training data, mirroring human perceptual abilities.

The big picture

This research bridges the gap between neuroscience and artificial intelligence, offering a potential blueprint for creating AI systems that mimic human cognitive abilities. The ability to learn from limited data – 'one-shot learning' – is a significant hurdle for current AI, and this discovery could unlock a new generation of AI models with dramatically improved efficiency and adaptability. The convergence of these fields has implications for a wide range of industries, from healthcare and robotics to autonomous vehicles and beyond.

What we're watching

Clinical Applications
Further investigation into the neurological disorders linked to impaired one-shot learning could lead to new diagnostic tools and therapeutic interventions for conditions like schizophrenia and Parkinson's disease.
AI Convergence
The pace at which AI models incorporate these neurological insights will determine the speed of advancement in areas requiring rapid learning and adaptation, such as robotics and autonomous systems.
Model Limitations
How the model's ability to encode abstract concepts will evolve, as the current research indicates it primarily captures pattern recognition rather than higher-level understanding, remains a key area of development.

NYU Langone Appoints GI Cancer Expert to Lead Perlmutter Cancer Center

Event summary

  • Anirban Maitra, MD, former scientific director of the Pancreatic Cancer Research Center at MD Anderson, has been appointed Director of the Perlmutter Cancer Center at NYU Langone Health.
  • Dr. Maitra previously co-directed NYU Langone's Gastrointestinal (GI) Cancer Center and served as associate director of translational research.
  • The appointment follows a national search initiated in March 2025 after Alec C. Kimmelman, MD, PhD, became Dean and CEO of NYU Langone Health.
  • NYU Langone recently established a Center for Molecular Oncology in October 2024, implementing liquid biopsies for personalized treatment plans.

The big picture

The appointment of a recognized leader like Dr. Maitra signals NYU Langone’s commitment to expanding its cancer research and treatment capabilities, particularly in personalized medicine. This move aligns with the broader trend in oncology towards precision therapies and early detection, and strengthens NYU Langone’s position as a leading Comprehensive Cancer Center in a highly competitive market. The integration of translational research, as emphasized by Dr. Maitra, is crucial for converting research breakthroughs into tangible clinical benefits.

What we're watching

Strategic Alignment
Dr. Maitra’s focus on biomarker development and early detection will likely accelerate the adoption of the Center for Molecular Oncology’s liquid biopsy program, potentially impacting patient outcomes and research output.
Competitive Landscape
Given Dr. Maitra’s prior leadership at MD Anderson, the move could intensify competition for clinical trials and research funding within the New York City cancer care market.
Research Funding
The success of Dr. Maitra’s leadership will depend on securing and managing large-scale, multi-institutional NIH and foundation-funded initiatives, similar to those he previously led.
CID: 370